Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sarepta Therapeutics ( SRPT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.1%. By the end of trading, Sarepta Therapeutics rose $0.51 (1.1%) to $48.03 on light volume. Throughout the day, 1,223,846 shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 1,891,900 shares. The stock ranged in a price between $46.64-$48.46 after having opened the day at $47.17 as compared to the previous trading day's close of $47.52. Other companies within the Drugs industry that increased today were: GW Pharmaceuticals PLC ADR ( GWPH), up 96.9%, Delcath Systems ( DCTH), up 91.4%, DARA Biosciences ( DARA), up 41.2% and Genvec ( GNVC), up 27.7%.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. Sarepta Therapeutics has a market cap of $1.6 billion and is part of the health care sector. Shares are up 84.5% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the negative front, StemCells ( STEM), down 12.5%, GTx ( GTXI), down 12.2%, Aoxing Pharmaceutical Company ( AXN), down 10.8% and PTC Therapeutics ( PTCT), down 9.1% , were all laggards within the drugs industry with Sanofi ( SNY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Sarepta Therapeutics Chart Patterns Look Good

Verastem Shares Are Exploding 50% -- Here's Why

Watch the Key Technical Levels

Net Seller, but Itching to Put More Cash to Work